NeuroScios GmbH   Report issue

For profit Phase 1 Phase 2
Founded: Graz Austria (2013)

Organization Overview

First Clinical Trial
2017
NCT03069014
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

NeuroScios, Austria | NeuroScios GmbH